Dec 2 (Reuters) - PTC Therapeutics ( PTCT ) has entered
into a licensing deal with a unit of Novartis AG for up
to $2.9 billion, the company said on Monday, for its
experimental drug being developed for a rare neurological
disorder.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj
Kalluvila)